Speaker illustration

Doctor Yan Liang

National Center for Cardiovascular Diseases, Beijing (China)

Dr. Liang, Yan, Female, Cardiologist, Medical Doctor, Doctoral Tutor She is Vice Director of Emergency, Cardiovascular Institute and FuWai Hospital, CAMS & PUMC. She has engaged in first line clinical works for more than 20 years in Fuwai hospital, has good experiences in diagnosis and treatment in severe and complicated patients. The main research fields are heart failure, arrhythmia, anticoagulation, antiplatelet therapy, etc. She has been working and trained in Population Health Research Institute (PHRI), McMaster University, Canada, and has involved in many large international clinical trails. She is the Steering Committee member of COMPASS trial, the International Adjudication Committee member of PURE, the National Leader of IVVE and INTERBLEED trials, the National Study Management Coordinator of HOPE-3, TIMACS, G-CHF, the site PI of AVERROES, etc. She is the current member of many academic committees in China, the head secretary or standing committee member in some committees.

Combination of low dose rivaroxaban and aspirin in females and males with chronic coronary artery disease or peripheral artery disease

Event: ESC CONGRESS 2019

Topic: Secondary Prevention

Session: Late Breaking Science in Cardiovascular Pharmacology

Thumbnail

ESC 365 is supported by

logo Novo Nordisk